AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2298357 — intervention group
Group type: EXPERIMENTAL
Intervention: Laxative preparation
Number of subjects: 56
Study 2298357 — intervention group
Group type: COMPARATOR
Intervention: Control group (no laxative preparation)
Number of subjects: 56
Study 6155029 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate, 440 mg total daily dose
Number of subjects: 10
Study 6155029 — intervention group
Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 10
Study 31981323 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis treatment
Number of subjects: 30
Study 31981323 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30
Study 30931663 — intervention group
Group type: EXPERIMENTAL
Intervention: Hi-Fatigue G
Number of subjects: 52
Study 30931663 — intervention group
Group type: COMPARATOR
Intervention: Palacos R + G
Number of subjects: 52
Study 28698347 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic no-touch OPCABG
Number of subjects: 360
Study 28698347 — intervention group
Group type: EXPERIMENTAL
Intervention: OPCABG with partial clamp applying carbon dioxide surgical field flooding
Number of subjects: 360
Study 28698347 — intervention group
Group type: COMPARATOR
Intervention: OPCABG with partial clamp (control)
Number of subjects: 360
Study 28698347 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 360
Study 25211364 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg·kg⁻¹)
Number of subjects: 26
Study 25211364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 22422304 — intervention group
Group type: COMPARATOR
Intervention: Cholecalciferol 2,000 IU daily
Number of subjects: 30
Study 22422304 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 5,000 IU daily
Number of subjects: 30
Study 21542916 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment as recommended by 4‐T staff
Number of subjects: 66
Study 21542916 — intervention group
Group type: EXPERIMENTAL
Intervention: 4‐T automated insulin dose adjustment algorithm
Number of subjects: 66
Study 21542916 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycaemic target of HbA(1c) ≤6.5%
Number of subjects: 66
Study 21542916 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptation of trial protocol by staff
Number of subjects: 66
Study 19762737 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine
Number of subjects: 24
Study 19762737 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium
Number of subjects: 24
Study 19762737 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 24
Study 17151589 — intervention group
Group type: EXPERIMENTAL
Intervention: Spread 1 (200 microg folic acid, 2 microg vitamin B(12), 1 mg vitamin B(6))
Number of subjects: 150
Study 17151589 — intervention group
Group type: EXPERIMENTAL
Intervention: Spread 2 (400 microg folic acid, 2 microg vitamin B(12), 1 mg vitamin B(6))
Number of subjects: 150
Study 17151589 — intervention group
Group type: COMPARATOR
Intervention: Control spread (no B-vitamins)
Number of subjects: 150
Study 15792014 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin, macro and microelement supplementation
Number of subjects: 0
Study 15792014 — intervention group
Group type: COMPARATOR
Intervention: Non-supplemented group
Number of subjects: 0
Study 15792014 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 11795353 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (SERM)
Number of subjects: 0
Study 11795353 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle and dietary changes (increasing weight-bearing activity, enhancing calcium and vitamin D intake)
Number of subjects: 0
Study 11795353 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 0
Study 11795353 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen/progestin therapy
Number of subjects: 0
Study 9692698 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosapride 40 mg q.d.s. for 2 days
Number of subjects: 21
Study 9692698 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 7919152 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (adenosine-receptor antagonist)
Number of subjects: 0
Study 7919152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3079536 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose/electrolyte solution designed for maintenance of hydration (Na+ concentration 45 mmol/l)
Number of subjects: 54
Study 3079536 — intervention group
Group type: COMPARATOR
Intervention: Oral glucose/electrolyte solution designed for fluid replacement (Na+ concentration 75 mmol/l)
Number of subjects: 54
Study 30064398 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month behavioral change intervention adapted from PREMIER
Number of subjects: 140
Study 30064398 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention (Arm 2)
Number of subjects: 140
Study 26504195 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI <18.5 kg/m2
Number of subjects: 85437
Study 26504195 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI 22.5-24.9 kg/m2
Number of subjects: 85437
Study 26504195 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI 25-27.4 kg/m2
Number of subjects: 85437
Study 26504195 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI 27.5-29.9 kg/m2
Number of subjects: 85437
Study 26504195 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI 30-34.9 kg/m2
Number of subjects: 85437
Study 26504195 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI 35-39.9 kg/m2
Number of subjects: 85437
Study 26504195 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI >40 kg/m2
Number of subjects: 85437
Study 26504195 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically determined BMI increase (per unit)
Number of subjects: 85437
Study 26504195 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational BMI increase (per unit)
Number of subjects: 85437
Study 24885548 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified Airway Risk Index (SARI)
Number of subjects: 28
Study 24885548 — intervention group
Group type: COMPARATOR
Intervention: Usual non‐specific assessment
Number of subjects: 28
Study 23327961 — intervention group
Group type: EXPERIMENTAL
Intervention: Urethral sphincter electromyography (US‐EMGs) in MSA patients
Number of subjects: 15
Study 22166652 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 14
Study 22166652 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 14
Study 18758747 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted, one-to-one education
Number of subjects: 172
Study 15544281 — intervention group
Group type: EXPERIMENTAL
Intervention: VR simulation and multimedia educational tool
Number of subjects: 0
Study 15544281 — intervention group
Group type: COMPARATOR
Intervention: Multimedia educational tool only
Number of subjects: 0
Study 15544281 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 11557312 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (12.5 mg/kg body weight) and N-acetyl-cysteine (10 mg/kg body weight) for 7 days
Number of subjects: 0
Study 11557312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9663892 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg folic acid and 4 g betaine daily for 12 weeks
Number of subjects: 30
Study 9663892 — intervention group
Group type: COMPARATOR
Intervention: 5 mg folic acid daily for 12 weeks
Number of subjects: 30
Study 9663892 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 or 5 mg folic acid daily for 40 weeks
Number of subjects: 30
Study 9663892 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 or 5 mg folic acid daily for 52 weeks
Number of subjects: 30
Study 7852661 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg cyanocobalamin (3 x/day)
Number of subjects: 27
Study 7852661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 3163217 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumferential supracrestal fiberotomy (CSF) procedure
Number of subjects: 320
Study 3163217 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CSF procedure)
Number of subjects: 320
Study 30125124 — intervention group
Group type: EXPERIMENTAL
Intervention: MacIntosh tenodesis with 20 N graft tension and tibia free to rotate
Number of subjects: 8
Study 30125124 — intervention group
Group type: EXPERIMENTAL
Intervention: MacIntosh tenodesis with 80 N graft tension and tibia free to rotate
Number of subjects: 8
Study 30125124 — intervention group
Group type: COMPARATOR
Intervention: MacIntosh tenodesis with 20 N graft tension and fixed tibial rotation
Number of subjects: 8
Study 30125124 — intervention group
Group type: COMPARATOR
Intervention: MacIntosh tenodesis with 80 N graft tension and fixed tibial rotation
Number of subjects: 8
Study 30125124 — intervention group
Group type: COMPARATOR
Intervention: Sectioning of the anterolateral complex
Number of subjects: 8
Study 26228939 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg Methylphenidate (MPH)
Number of subjects: 15
Study 26228939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 23300127 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy for Antidepressants (META)
Number of subjects: 50
Study 23300127 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 50
Study 21361737 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingesting 10 tablets (four acetaminophen, four ibuprofen, and two multivitamin tablets) with 500 ml of water
Number of subjects: 15
Study 21361737 — intervention group
Group type: COMPARATOR
Intervention: Drinking 500 ml of water alone (control group)
Number of subjects: 15
Study 21361737 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography technique
Number of subjects: 15
Study 18082496 — intervention group
Group type: EXPERIMENTAL
Intervention: C + ASA
Number of subjects: 70
Study 18082496 — intervention group
Group type: COMPARATOR
Intervention: ASA
Number of subjects: 70
Study 16483870 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino Acid (AA) supplementation
Number of subjects: 17
Study 16483870 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 17
Study 12538743 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg orally for 6 weeks)
Number of subjects: 10
Study 12538743 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (100 mg orally for 6 weeks)
Number of subjects: 10
Study 12538743 — intervention group
Group type: COMPARATOR
Intervention: Control (no antihypertensive drugs except diuretics)
Number of subjects: 10
Study 11195946 — intervention group
Group type: EXPERIMENTAL
Intervention: Study doctors interpreting tympanograms
Number of subjects: 242
Study 11195946 — intervention group
Group type: COMPARATOR
Intervention: Curves taken during pre-scheduled healthy visits
Number of subjects: 242
Study 11195946 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent knowledge of clinical ear status
Number of subjects: 242
Study 11195946 — intervention group
Group type: COMPARATOR
Intervention: Audiologist interpreting tympanograms
Number of subjects: 242
Study 9123730 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat sextant biopsy
Number of subjects: 89
Study 9123730 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative repeat biopsy
Number of subjects: 89
Study 9123730 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive repeat biopsy
Number of subjects: 89
Study 8349185 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 11
Study 8349185 — intervention group
Group type: COMPARATOR
Intervention: Control (no GM-CSF)
Number of subjects: 11
Study 3812946 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 ml 0.5% prilocaine
Number of subjects: 6
Study 3812946 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml 1% prilocaine
Number of subjects: 6
Study 3812946 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 ml 1% prilocaine
Number of subjects: 6
Study 3812946 — intervention group
Group type: COMPARATOR
Intervention: Control (100% flexion remaining)
Number of subjects: 6
Study 3812946 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg prilocaine
Number of subjects: 6
Study 31539292 — intervention group
Group type: EXPERIMENTAL
Intervention: BCI condition (commercial EEG-based BCI)
Number of subjects: 26
Study 31539292 — intervention group
Group type: COMPARATOR
Intervention: Traditional condition (standard keyboard and mouse interface)
Number of subjects: 26
Study 29575488 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal connection and microthreads on the implant neck (I MT)
Number of subjects: 21
Study 29575488 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal connection, no microthreads (I NMT)
Number of subjects: 21
Study 29575488 — intervention group
Group type: EXPERIMENTAL
Intervention: External connection, with microthreads (E MT)
Number of subjects: 21
Study 29575488 — intervention group
Group type: EXPERIMENTAL
Intervention: External connection, without microthreads (E NMT)
Number of subjects: 21
Study 26345106 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing plus 375 mg amoxicillin and 250 mg metronidazole for 7 days
Number of subjects: 39
Study 26345106 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing + placebo
Number of subjects: 39
Study 23905537 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist responsiveness in the first two sessions of therapy (Cognitive Behavior Therapy and Interpersonal Psychotherapy)
Number of subjects: 0
Study 23905537 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative therapist behavior factor
Number of subjects: 0
Study 23905537 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist attentiveness and early empathic responding
Number of subjects: 0
Study 22476270 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and feedback intervention in group A (5 units) during intervention period 1
Number of subjects: 10
Study 22476270 — intervention group
Group type: COMPARATOR
Intervention: Control group B (5 units) during intervention period 2
Number of subjects: 10
Study 20124051 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate therapy for 28 days
Number of subjects: 300
Study 20124051 — intervention group
Group type: COMPARATOR
Intervention: No iron therapy
Number of subjects: 300
Study 20124051 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate therapy
Number of subjects: 300
Study 19103540 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) added to induction cardioplegia solution at a dose of 4 mmol/l and to maintenance cardioplegia solution at a dose of 2 mmol/l
Number of subjects: 30
Study 19103540 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 30
Study 19103540 — intervention group
Group type: COMPARATOR
Intervention: Control group (no NAC)
Number of subjects: 30
Study 15614301 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous sedation
Number of subjects: 197
Study 15614301 — intervention group
Group type: COMPARATOR
Intervention: Local anesthesia
Number of subjects: 197
Study 11127492 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational group sessions and individual sessions administered by a trained nurse and physiotherapist for COPD patients.
Number of subjects: 140
Study 11127492 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention) for COPD patients.
Number of subjects: 140
Study 11127492 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention for asthmatics.
Number of subjects: 140
Study 11127492 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention) for asthmatics.
Number of subjects: 140
Study 9344484 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrieval cue exposure
Number of subjects: 0
Study 9344484 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased exposure to retrieval cue
Number of subjects: 0
Study 9344484 — intervention group
Group type: COMPARATOR
Intervention: Retention intervals associated with remote memory
Number of subjects: 0
Study 9344484 — intervention group
Group type: COMPARATOR
Intervention: Retention intervals associated with intermediate memory
Number of subjects: 0
Study 8455046 — intervention group
Group type: EXPERIMENTAL
Intervention: Decisional aid for mental capacity assessments
Number of subjects: 64
Study 8455046 — intervention group
Group type: COMPARATOR
Intervention: No decisional aid (Control)
Number of subjects: 64
Study 3101243 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular iron dextran prophylaxis
Number of subjects: 0
Study 3101243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31439101 — intervention group
Group type: EXPERIMENTAL
Intervention: Factual gain‐framed message
Number of subjects: 402
Study 31439101 — intervention group
Group type: EXPERIMENTAL
Intervention: Factual loss‐framed message
Number of subjects: 402
Study 31439101 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional gain‐framed message
Number of subjects: 402
Study 31439101 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional loss‐framed message
Number of subjects: 402
Study 29089053 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluralaner (1.5 mg/kg body weight, 4 administrations, 7 days apart)
Number of subjects: 432
Study 29089053 — intervention group
Group type: COMPARATOR
Intervention: Control (non-medicated drinking water)
Number of subjects: 432
Study 26474617 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency surgery (Group A) within 6 hours after injury
Number of subjects: 40
Study 26474617 — intervention group
Group type: COMPARATOR
Intervention: Selective surgery (Group B) after close reduction and improvement of soft tissue condition
Number of subjects: 40
Study 24019110 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam (3,750 mg once daily) administered simultaneously with glimepiride
Number of subjects: 0
Study 24019110 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam (3,750 mg once daily) administered simultaneously with glipizide ER
Number of subjects: 0
Study 24019110 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam (3,750 mg once daily) administered simultaneously with olmesartan medoxomil
Number of subjects: 0
Study 24019110 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam (3,750 mg once daily) administered 4 hours before glimepiride
Number of subjects: 0
Study 24019110 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam (3,750 mg once daily) administered 4 hours before glipizide ER
Number of subjects: 0
Study 24019110 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam (3,750 mg once daily) administered 4 hours before olmesartan medoxomil
Number of subjects: 0
Study 21781231 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc-aluminium ointment
Number of subjects: 50
Study 21781231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 20087302 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA supplementation (0.8% BCAA in a 3.5% carbohydrate solution; 2,500 mL/day)
Number of subjects: 12
Study 20087302 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink (isocaloric)
Number of subjects: 12
Study 17535868 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 8
Study 17535868 — intervention group
Group type: EXPERIMENTAL
Intervention: No treatment (untreated TS)
Number of subjects: 8
Study 17535868 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 8
Study 15008021 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture Group (AG)
Number of subjects: 15
Study 15008021 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve Stimulation Group (NSG)
Number of subjects: 15
Study 15008021 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 15
Study 10730601 — intervention group
Group type: EXPERIMENTAL
Intervention: Actor of mixed race (Hispanic-black)
Number of subjects: 231
Study 10730601 — intervention group
Group type: COMPARATOR
Intervention: White actor
Number of subjects: 231
Study 10730601 — intervention group
Group type: EXPERIMENTAL
Intervention: Female actress
Number of subjects: 231
Study 10730601 — intervention group
Group type: COMPARATOR
Intervention: Male actor
Number of subjects: 231
Study 9168213 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 60 mg administered directly in the surgical site (mixed with local anesthetic)
Number of subjects: 30
Study 9168213 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac 60 mg administered via the parenteral route
Number of subjects: 30
Study 1438525 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (400 mg b.d.)
Number of subjects: 238
Study 1438525 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg b.d.) with MMSC (500 mg four times daily)
Number of subjects: 238
Study 1438525 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg b.d.) with cysteine (200 mg four times daily)
Number of subjects: 238
Study 1438525 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine at night (maintenance)
Number of subjects: 238
Study 1438525 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine with MMSC (maintenance)
Number of subjects: 238
Study 1438525 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine with cysteine (maintenance)
Number of subjects: 238
Study 1438525 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine alone (previous treatment)
Number of subjects: 238
Study 2410683 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (5.7 mg/day)
Number of subjects: 15
Study 2410683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31074201 — intervention group
Group type: COMPARATOR
Intervention: Intralesional corticosteroids (ILCs)
Number of subjects: 80
Study 31074201 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 80
Study 31074201 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (ILCs and PRP)
Number of subjects: 80
Study 28929782 — intervention group
Group type: EXPERIMENTAL
Intervention: Autobiographical memory intervention (Precious Memories)
Number of subjects: 86
Study 28929782 — intervention group
Group type: COMPARATOR
Intervention: Control condition (individual unstructured contacts with a volunteer)
Number of subjects: 86